-
Company Insights
NewAir France – Digital Transformation Strategies
Air France-KLM is an international airline group specializing in air passenger transport, cargo transport, and aircraft maintenance. The group offers flights to over 300 destinations in 120 countries through its Air France, KLM Royal Dutch Airlines (KLM), and Transavia airline brands; aircraft maintenance services through its Air France Industries KLM Engineering & Maintenance (AFI KLM E&M) group company and air freight services through its Air France-KLM-Martinair Cargo (AFKLMP Cargo) group company. Air France-KLM’s central hubs are in Amsterdam-Schiphol and Paris-Charles...
-
Product Insights
NewMicromobility in Insurance – Market Trends and Dynamics, 2024
Micromobility in Insurance Market Report Overview Micromobility is a term used to describe the range of lightweight vehicles designed for one or two people. It largely constitutes bicycles, e-bikes, and e-scooters and is a particularly popular form of first- and last-mile transport in urban environments. City planners and policymakers are using micromobility to encourage less private vehicle usage as part of their net-zero strategies. Shared mobility services are growing in popularity across most major cities as younger consumers make use...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Camrelizumab (Airuika)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pucotenlimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Pucotenlimab (Puyouheng)...
-
Thematic Analysis
Global M&A Deals in 2023 – Top Themes by Sector – Thematic Intelligence
If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&As). This report analyzes the disruptive themes that have driven M&A activity in 2023 across all sectors including automotive, basic material, business and consumer services, consumer, energy, financial, healthcare, industrials, real estate, technology, media & telecoms, transportation, infrastructure, and logistics.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRG-022 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRG-022 in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRG-022 in Acute Lymphocytic Leukemia (ALL, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRG-022 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRG-022 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRG-022 in B-Cell Acute Lymphocytic Leukemia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRG-022 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRG-022 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRG-022 in Diffuse Large B-Cell Lymphoma Drug Details: CRG-022 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CRG-022 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CRG-022 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CRG-022 in Follicular Lymphoma Drug Details: CRG-022 is under development for the...